Forecast Ledgerinterventional psychiatry and psychedelic medicineQuoted, dated predictions scored against public outcomes under one written method. Every score links to the words, the rule and the evidence.

True · Brier 0.02

Rules 1.1.0 · as of 14 Sep 2026

Quote

“Notably, the likelihood that in-office visits will immediately return for everybody everywhere is low. ... I am confident about that statement because I understand that somebody would probably lose their job if that's what happened.”
· A Crucial Update on Prescribing Controlled Substances Past May 11th That Explains Everything And Removes All Doubt and Worry · substack post Paid

Prediction that the DEA will not let the in-person visit requirement for controlled-substance prescribing snap back for all telehealth patients when the PHE ends May 11, 2023. Reasoning: organizational self-preservation at the DEA; a snap-back would be a public health disaster with congressional hearings.

Intake

EventA proposition written from a template on the asset, with a resolution criterion and a named public source, before the outcome is looked up. The same event resolves every person's items on it. Method ›
DEA extends the COVID-era telemedicine flexibilities for controlled-substance prescribing past the PHE end
AreaOne of five topic classes: regulatory decisions, clinical trial outcomes, company and market outcomes, payer and policy, practice adoption. Every event has one area. Method ›
Regulatory decisions
DeadlineThe date by which the event must happen for the item to be true. It comes only from the person's words through the anchor table. Method ›
11 May 2023 Stated · “immediately (at the PHE end); on May 11”
Probability
0.70 LexiconThe fixed five-bin table that turns a phrase into a probability. The strongest phrase in the claim sentence decides; coders never read tone. Method › · binOne of five lexicon steps: A 'will' 0.90, B 'probably' 0.70, C 'may' 0.50, D 'unlikely' 0.30, E 'never' 0.10. A stated number goes to the nearest bin for calibration only. Method › D · “the likelihood that in-office visits will immediately return for everybody everywhere is low” · denialA statement that the event will not happen. Its probability on the event side is 1 minus the bin value. Method ›
Base rateThe probability a published external study gives an event of that class and stage, fixed at intake. Halved when the item window is shorter than the class median time to decision. Never learned from the ledger's own items. Method ›
None in the table
Tags
denial, retrospective
Coder BCohen's kappa: agreement between two coders beyond chance, from -1 to 1. Reported for admit, event, deadline, bin and asserts from the second-coder match test. Method ›
admittedA statement that passed intake: sincere, the person's own claim, forward-looking, inside the five areas, and not excluded by a reason code. Only admitted statements become items. Method › · event E-0014 · deadline 11 May 2023 · bin D
Registry entry

DEA issues a rule or order that extends the COVID-era telemedicine flexibilities for prescribing controlled substances beyond the end of the COVID-19 public health emergency.

TRUE on the Federal Register publication date (or the DEA announcement date, if earlier) of a temporary rule or order that extends the COVID-era telemedicine flexibilities for prescribing controlled substances beyond the end of the COVID-19 public health emergency, so that the Ryan Haight Act in-person visit requirement does not return for telehealth patients at the PHE end. A proposed rule is not an extension. FALSE when the flexibilities expire at the PHE end with no such rule or order published, and FALSE at the deadline when no extension appears in the Federal Register. Resolution source: the Federal Register.

Resolution source: Federal Register

Readings: 'The Ryan Haight Act returns', 'in-office visits return for everybody everywhere' and an 'instant' return to in-person providers are read as the in-person requirement applying again to all telehealth controlled-substance patients at the PHE end.; Any DEA rule or order that continues remote prescribing of controlled substances without an in-person visit past the PHE end counts as an extension.

How to read
The event, criterion and deadline were written at intake, before the outcome1 if the registry event happened on or before the item's deadline, 0 if it did not. Written by a resolver who never sees p. Method › was looked up. Coder B coded the statement independently.

Coder A

Resolution

State
True
Effective deadlineAn item enters the score only when its deadline has passed and the outcome is true or false. A claim already known true still waits for its deadline. Method ›
11 May 2023
Outcome1 if the registry event happened on or before the item's deadline, 0 if it did not. Written by a resolver who never sees p. Method ›
occurred on 9 May 2023 · checked through 13 Sep 2026
Resolver note
Criterion: the FR publication date, or the earlier DEA announcement date, of a temporary rule or order extending the COVID-era telemedicine flexibilities past the PHE end so the Ryan Haight in-person requirement did not return. DEA and SAMHSA announced the 'Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications' on 2023-05-09; it was published 2023-05-10 (88 FR 30037, Docket DEA-407) and took effect 2023-05-11, the PHE end date, keeping the full flexibilities through 2023-11-11 with a one-year grace period to 2024-11-11 for relationships formed by then. Date set to the DEA announcement, 2023-05-09, as the criterion directs. The dea.gov page returned HTTP 403 to automated fetching; its date is fixed by the URL path, the search index and the AAMC item of 2023-05-12 ('On May 9 ... published'), and its content by the FR text.
BrierThe squared gap between a probability and the outcome, (p - o)^2. 0 is perfect, 0.25 is the constant coin flip, 1 is confidently wrong. Lower is better. Method ›
0.02 = (0.87 − 1)²
RestatementsAll of one person's items on one registry event. A cluster is one observation in every metric, so a claim repeated six times still gets one vote. Method ›
owen-0454owen-0457owen-0458
Adversarial recheck

escalated (date): The criterion fixes the date at the DEA announcement date when it is earlier than Federal Register publication. The resolver used DEA's press release of 2023-05-09 on the temporary rule (filed 2023-05-09, published 2023-05-10, effective 2023-05-11). DEA made an earlier public announcement: the Administrator's statement of 2023-05-03 (dea.gov, dated in its URL and quoted by K&L Gates and trade press; dea.gov refuses automated fetches) said DEA had received a record 38,000 comments and 'we have decided to extend the current flexibilities while we work to find a way forward'. Read as the DEA announcement of the extension, the first-true date is 2023-05-03. Read strictly, the statement announced a decision but no rule or order, and the rule was first announced on 2023-05-09. The criterion does not say which announcement counts. The state is unaffected; the date needs a ruling.

How to read
State at window close; the outcome comes from the registry, the score from the rule.

Registry

Timeline

1 claim against 60 events in the field.

saiddueevent
5 May 2023 · Oregon Psilocybin Services: Oregon issues its first psilocybin service center license (EPIC Healing Eugene);10 May 2023 · DEA and HHS: First temporary extension of COVID-19 telemedicine flexibilities for controlled 23 May 2023 · Colorado Governor Polis: Governor signs SB23-290 (Natural Medicine Regulation and Legalization), creating26 Jun 2023 · FDA: FDA issues draft guidance 'Psychedelic Drugs: Considerations for Clinical Invest1 Jul 2023 · TGA (Australia): Rescheduling takes effect: authorised psychiatrists may prescribe MDMA for PTSD 4 Aug 2023 · Sage Therapeutics / Biogen (zuranolone): FDA approves Zurzuvae (zuranolone) as the first oral treatment for postpartum de29 Aug 2023 · HHS: HHS recommends to DEA that marijuana be moved from Schedule I to Schedule III of7 Oct 2023 · California Governor Newsom: Newsom vetoes SB 58, which would have decriminalized psilocybin and other plant 10 Oct 2023 · DEA and HHS: Second temporary extension of telemedicine flexibilities for controlled medicati10 Oct 2023 · FDA: FDA warns patients and providers about risks of compounded ketamine products, in18 Oct 2023 · FDA / Janssen: FDA approves Spravato labeling supplement S-012 (package insert update).13 Dec 2023 · DEA: DEA again proposes placing DOI and DOC (phenethylamine research hallucinogens) iDEA: DEA AGAIN PROPOSES PLACING DOI AND DOC (PHENETHYLAMINE RESEARCH HALLUCINOGENS) I13 Feb 2024 · FDA / Lykos Therapeutics: FDA accepts Lykos's NDA for midomafetamine (MDMA)-assisted therapy for PTSD with7 Mar 2024 · FDA / MindMed: FDA grants Breakthrough Therapy designation to MM120 (LSD D-tartrate) for genera13 Mar 2024 · Cybin (CYB003): FDA grants Breakthrough Therapy Designation to CYB003 for adjunctive treatment o13 Mar 2024 · FDA / Cybin: FDA grants Breakthrough Therapy designation to CYB003 (deuterated psilocybin ana21 Mar 2024 · Utah Legislature: SB 266 becomes law without the governor's signature, allowing large Utah health 26 Mar 2024 · Neuronetics (NeuroStar): FDA clears NeuroStar TMS as a first-line adjunct for MDD in adolescents aged 15 16 Apr 2024 · European Medicines Agency: EMA holds a multi-stakeholder workshop 'Psychedelics: towards an EU regulatory f21 May 2024 · DOJ / DEA: DOJ publishes proposed rule to transfer marijuana from Schedule I to Schedule II4 Jun 2024 · FDA PDAC / Lykos Therapeutics (midomafetamine): FDA Psychopharmacologic Drugs Advisory Committee votes against MDMA-assisted the4 Jun 2024 · FDA Psychopharmacologic Drugs Advisory Committee: Advisory committee votes 2-9 that MDMA-assisted therapy is not shown effective f7 Jun 2024 · DEA: DEA stays the June 10, 2024 administrative hearing on Schedule I placement of DO9 Aug 2024 · FDA / Lykos Therapeutics: FDA issues a complete response letter (dated August 8) for MDMA capsules for PTS9 Aug 2024 · Lykos Therapeutics (midomafetamine): FDA issues a Complete Response Letter for MDMA-assisted therapy in PTSD and asks29 Aug 2024 · DEA: DEA publishes notice of an administrative hearing on the proposed marijuana resc26 Sep 2024 · Bristol Myers Squibb (Cobenfy / KarXT): FDA approves Cobenfy (xanomeline-trospium), the first muscarinic agonist for sch4 Nov 2024 · FDA / Janssen: FDA approves Spravato labeling supplement S-015 (package insert revision).5 Nov 2024 · Massachusetts voters: Massachusetts Question 4, a regulated natural psychedelics measure, fails with 419 Nov 2024 · DEA and HHS: Third temporary extension of telemedicine flexibilities for controlled medicatio31 Dec 2024 · Colorado Natural Medicine Division: Colorado begins accepting natural medicine business license applications; the re31 Dec 2024 · FDA / Janssen: FDA approves Spravato REMS modification S-013.13 Jan 2025 · DEA Administrative Law Judge: DEA's chief ALJ cancels the January 21, 2025 marijuana rescheduling hearing pend17 Jan 2025 · DEA: DEA publishes proposed rule creating special registrations for telemedicine pres17 Jan 2025 · DEA and HHS: Final rules allow a six-month buprenorphine supply via audio-only telemedicine a21 Jan 2025 · FDA / Johnson & Johnson: FDA approves Spravato (esketamine) as monotherapy for adults with treatment-resi21 Jan 2025 · Johnson & Johnson (Spravato): FDA approves Spravato as the first monotherapy for treatment-resistant depressio24 Mar 2025 · DEA and HHS: DEA and HHS delay the effective date of the buprenorphine and VA telemedicine fi24 Mar 2025 · FDA / Janssen: FDA approves Spravato REMS modification S-018; the REMS still requires certified31 Mar 2025 · Colorado Natural Medicine Division: Colorado issues its first healing center license to The Center Origin (announced7 Apr 2025 · New Mexico Governor Lujan Grisham: Governor signs SB 219, the Medical Psilocybin Act (effective June 20, 2025): DOH15 May 2025 · FDA / Janssen: FDA approves Spravato REMS modification S-021: minor revision to the Patient Mon16 May 2025 · FDA Commissioner Marty Makary: Makary tells NewsNation the FDA will give psychedelic trial data 'an expeditious24 Jun 2025 · HHS Secretary Robert F. Kennedy Jr.: At a House Energy and Commerce hearing, Kennedy says HHS is 'working very hard' 10 Jul 2025 · Czech Senate: Czech Senate gives final approval to a law allowing medical use of psilocybin fr11 Jul 2025 · BfArM (Germany): BfArM approves the EU's first compassionate use programme for psilocybin in trea18 Jul 2025 · Otsuka / Lundbeck (Rexulti, PTSD): FDA advisory committee votes against brexpiprazole plus sertraline for PTSD, cit31 Jul 2025 · FDA / Janssen: FDA approves Spravato REMS modification S-024.4 Sep 2025 · FDA: FDA publicly releases the Lykos MDMA complete response letter, citing unreported4 Sep 2025 · FDA / Lykos Therapeutics: FDA publicly releases the August 2024 Lykos CRL, detailing concerns on safety re18 Sep 2025 · BrainsWay (Deep TMS): FDA clears BrainsWay's accelerated Deep TMS protocol for MDD, shortening treatme22 Sep 2025 · Otsuka / Lundbeck (Rexulti, PTSD): FDA issues a CRL for brexpiprazole plus sertraline in PTSD, citing insufficient 9 Oct 2025 · FDA / Janssen: FDA approves Spravato REMS modification S-025 with vendor-related changes to the6 Nov 2025 · Johnson & Johnson (Caplyta, adjunctive MDD): FDA approves Caplyta (lumateperone) as adjunctive treatment for MDD based on two13 Nov 2025 · BrainsWay (Deep TMS): FDA clears BrainsWay Deep TMS as an adjunct for MDD in adolescents aged 15 to 215 Dec 2025 · New Mexico Department of Health: At the Medical Psilocybin Advisory Board's first meeting, DOH says patient acces18 Dec 2025 · President Trump: Executive order directs the Attorney General to complete marijuana rescheduling 31 Dec 2025 · DEA and HHS: Fourth temporary extension of telemedicine flexibilities for controlled medicati1 Jan 2026 · Czech Republic: Czech medical psilocybin framework takes effect: psychiatrists may administer ps5 Jan 2026 · GH Research (GH001): FDA lifts the clinical hold on GH001, clearing a global phase 3 program in TRD tDEA EXTENDS THE C…DEA extends the COVID-era telemedicine flexibilities for controlled-substance prescribing past the PHE end · stated 1 May 2023DEA extends the COVID-era telemedicine flexibilities for controlled-substance prescribing past the PHE end · restated 1 May 2023 · p 70%DEA extends the COVID-era telemedicine flexibilities for controlled-substance prescribing past the PHE end · restated 1 May 2023 · p 70%DEA extends the COVID-era telemedicine flexibilities for controlled-substance prescribing past the PHE end · restated 1 May 2023 · p 90%DEA extends the COVID-era telemedicine flexibilities for controlled-substance prescribing past the PHE end · restated 1 May 2023 · p 90%DEA extends the COVID-era telemedicine flexibilities for controlled-substance prescribing past the PHE end · hit 9 May 2023TODAY202420252026

Regulatory decisions